Conservative treatment of venous thromboembolism

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10321801" target="_blank" >RIV/00216208:11110/15:10321801 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10321801

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S2212021115300072" target="_blank" >http://www.sciencedirect.com/science/article/pii/S2212021115300072</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rvm.2015.06.002" target="_blank" >10.1016/j.rvm.2015.06.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Conservative treatment of venous thromboembolism

Popis výsledku v původním jazyce

Venous thromboembolism is a frequent and serious vascular disease that can lead to serious complications. Rational and accurate establishment of the diagnosis enables early treatment that reduces the occurrence and severity of acute and chronic complications. Conservative treatment of this disease has reached a turning point with the introduction of novel direct oral anticoagulants. According to present guidelines, standard treatment with low molecular heparines such as Fondaparinux and vitamine K antagonists still remain a clinically effective therapeutic option not only in the acute phase, but also in the secondary and long term prophylaxis of the disease. Direct oral anticoagulants represent an important alternative to conventional anticoagulants and appeared in new ESC recommendations of pulmonary embolism.

Název v anglickém jazyce

Conservative treatment of venous thromboembolism

Popis výsledku anglicky

Venous thromboembolism is a frequent and serious vascular disease that can lead to serious complications. Rational and accurate establishment of the diagnosis enables early treatment that reduces the occurrence and severity of acute and chronic complications. Conservative treatment of this disease has reached a turning point with the introduction of novel direct oral anticoagulants. According to present guidelines, standard treatment with low molecular heparines such as Fondaparinux and vitamine K antagonists still remain a clinically effective therapeutic option not only in the acute phase, but also in the secondary and long term prophylaxis of the disease. Direct oral anticoagulants represent an important alternative to conventional anticoagulants and appeared in new ESC recommendations of pulmonary embolism.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reviews in Vascular Medicine

ISSN

2212-0211

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

6

Strana od-do

6-11

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-84947708540